208 related articles for article (PubMed ID: 16707419)
1. Targeting Aurora kinases for the treatment of prostate cancer.
Lee EC; Frolov A; Li R; Ayala G; Greenberg NM
Cancer Res; 2006 May; 66(10):4996-5002. PubMed ID: 16707419
[TBL] [Abstract][Full Text] [Related]
2. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation.
Chieffi P; Cozzolino L; Kisslinger A; Libertini S; Staibano S; Mansueto G; De Rosa G; Villacci A; Vitale M; Linardopoulos S; Portella G; Tramontano D
Prostate; 2006 Feb; 66(3):326-33. PubMed ID: 16267859
[TBL] [Abstract][Full Text] [Related]
3. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer.
Jeet V; Russell PJ; Verma ND; Khatri A
Curr Cancer Drug Targets; 2012 Feb; 12(2):144-63. PubMed ID: 22229247
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
[TBL] [Abstract][Full Text] [Related]
5. Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.
Shionome Y; Yan L; Liu S; Saeki T; Ouchi T
PLoS One; 2013; 8(1):e55457. PubMed ID: 23383195
[TBL] [Abstract][Full Text] [Related]
6. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation.
Moretti L; Niermann K; Schleicher S; Giacalone NJ; Varki V; Kim KW; Kopsombut P; Jung DK; Lu B
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1189-97. PubMed ID: 21514073
[TBL] [Abstract][Full Text] [Related]
7. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
8. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
9. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
10. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
12. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R
Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665
[TBL] [Abstract][Full Text] [Related]
13. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells.
Evans R; Naber C; Steffler T; Checkland T; Keats J; Maxwell C; Perry T; Chau H; Belch A; Pilarski L; Reiman T
Leuk Lymphoma; 2008 Mar; 49(3):559-69. PubMed ID: 18297535
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.
Matarasso N; Bar-Shira A; Rozovski U; Rosner S; Orr-Urtreger A
Neoplasia; 2007 Sep; 9(9):707-15. PubMed ID: 17898866
[TBL] [Abstract][Full Text] [Related]
15. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
Chowdhury A; Chowdhury S; Tsai MY
Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase inhibitors as anticancer molecules.
Katayama H; Sen S
Biochim Biophys Acta; 2010; 1799(10-12):829-39. PubMed ID: 20863917
[TBL] [Abstract][Full Text] [Related]
17. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
Paller CJ; Wissing MD; Mendonca J; Sharma A; Kim E; Kim HS; Kortenhorst MS; Gerber S; Rosen M; Shaikh F; Zahurak ML; Rudek MA; Hammers H; Rudin CM; Carducci MA; Kachhap SK
Cancer Med; 2014 Oct; 3(5):1322-35. PubMed ID: 24989836
[TBL] [Abstract][Full Text] [Related]
18. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
[TBL] [Abstract][Full Text] [Related]
19. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.
Tyler RK; Shpiro N; Marquez R; Eyers PA
Cell Cycle; 2007 Nov; 6(22):2846-54. PubMed ID: 18032922
[TBL] [Abstract][Full Text] [Related]
20. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]